Clinical trials: Meningococcal
Meningitis, Meningococcal
A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine
This study is a randomized, double-blinded, and controlled phase III clinical trial of the Group A meningococcal polysaccharide vaccine to evaluate the safety and immunogenicity of the vaccine in healthy infants aged 6-15 months.
- Trial name
- NCT04689165
- Testing
- Experimental Group A meningococcal polysaccharide vaccine, Control Group A meningococcal polysaccharide vaccine
- Where
- China
- Volunteers
- 1,280 people, healthy volunteers welcome
- Sponsor
- Wei Cun
Prematurity, Vaccination
Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B
In the UK, babies receive their vaccinations according to a standard schedule, irrespective of their gestation at birth. This policy is designed so that all babies are protected as early as possible from vaccine preventable…
- Conditions
- Prematurity, Vaccination, Meningococcal Disease
- Trial name
- BEAR Men B (NCT03125616)
- Testing
- 4CMenB Vaccine
- Where
- United Kingdom
- Volunteers
- 136 people
- Sponsor
- St George's, University of London
Infections, Meningococcal, Meningococcal Vaccines
Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children
The purpose of the study is to evaluate the persistence of the immune response of GSK134612 vaccine up to 68 months after vaccination in the primary vaccination study (NCT number = NCT00674583) of 2 to 10 year old subjects.
- Trial name
- NCT01266993
- Testing
- Nimenrix (GSK134612 vaccine), Menjugate
- Where
- 24 sites in France, Germany
- Volunteers
- 271 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Streptococcus Pneumonia, Streptococcus Pyogenes Infection
Evaluation of Post Infectious Inflammatory Reaction (PIIR) Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection
As Covid 19 manifestations that have been recently described, inflammatory manifestation have major impact in infectious disease lesions.
- Conditions
- Streptococcus Pneumonia, Streptococcus Pyogenes Infection, Neisseria Meningitides Meningitis
- Trial name
- RIPI (NCT04594785)
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Montpellier
Infections, Meningococcal, Meningococcal Vaccines
Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects
The purpose of this study is to demonstrate, in 2-10 year old subjects, the non-inferiority of meningococcal vaccine GSK134612 compared to licensed meningococcal vaccine Mencevax™.
- Trial name
- NCT00514904
- Testing
- Nimenrix, Mencevax
- Where
- 7 sites in India, Lebanon and 2 more
- Volunteers
- 1,504 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
MENINGOCOCCAL INFECTION
A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
This study is looking at a new vaccine that might prevent meningococcal disease, and will study the immune response elicited by this vaccine when given to healthy young children.
- Trial name
- NCT02531698
- Testing
- Bivalent rLP2086 Vaccine, Licensed pediatric hepatits A vaccine, Normal Saline
- Where
- 15 sites in Finland, Poland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hematopoietic Stem Cell Transplant, Meningococcal Vaccine
Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplant (HSCT) recipients are at risk of various bacterial infections, especially due to a progressive decrease of specific antibodies.
- Trial name
- MENINGREF (NCT03509051)
- Testing
- B vaccination
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Meningococcal ACWY Disease
A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).
This study will evaluate the immunogenicity, reactogenicity and safety of a booster dose of MenACWY-TT vaccine administered 10 years after healthy subjects aged 11-17 years received either MenACWY-TT vaccine (Nimenrix) or…
- Trial name
- NCT03189745
- Testing
- MenACWY-TT
- Where
- Philippines
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections, Meningococcal Infections
Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines
The purpose of the study is to evaluate the immune responses of UK infants after one or two doses of pneumococcal conjugate vaccine or one or two doses of three different types of meningococcal conjugate vaccine given at either…
- Trial name
- sched1 (NCT00197808)
- Testing
- menjugate, Men C conjugate vaccine, Men C conjugate
- Where
- 2 sites in United Kingdom
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Public Health England
Meningococcal Meningitis
Comparison of Two Meningococcal ACWY Conjugate Vaccines
There is evidence of waning immunity in individuals vaccinated against meningitis C as part of the UK infant immunisation schedule.
- Trial name
- PRIME (NCT01192997)
- Testing
- Menveo, MenACWY-TT
- Where
- 3 sites in United Kingdom
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Public Health England
Meningococcal Disease, Pneumococcal Disease
Hepatitis B Vaccination in Infants
In the UK, infants currently receive a 5-in-1 vaccine (Pediacel) at 2, 3 and 4 months of age, which protects against diphtheria, tetanus, pertussis (whooping cough), polio and Haemophilus influenzae type b (Hib).
- Conditions
- Meningococcal Disease, Pneumococcal Disease, Haemophilus Influenzae Serotype b Disease, Diphtheria, Tetanus and Pertussis
- Trial name
- Infanrix (NCT01896596)
- Testing
- Menjugate, Menitorix, NeisVac-C
- Where
- United Kingdom
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Public Health England
Infections, Meningococcal
Safety of 4CMenB Exposure During Pregnancy
4CMenB was approved by the Food and Drug Administration (FDA) in the United States in January 2015 for people aged 10 through 25 years of age.
- Trial name
- NCT02640677
- Testing
- 4CMenB
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- GlaxoSmithKline
Meningococcal Disease, Infections, Meningococcal
Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.
Assess the safety and immunogenicity of a 3-dose schedule (at 2, 4, 6 months) of GSK Biologicals' Meningococcal B recombinant vaccine followed by a booster at 12 months when concomitantly administered with routine vaccines in…
- Trial name
- NCT02173704
- Testing
- Bexsero®, Routine vaccines
- Where
- 2 sites in Taiwan
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Disease, Infections, Meningococcal
A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)
The purpose of this study is to evaluate persistence of bactericidal antibodies for N. meningitidis serogroups A, C, W, and Y and serogroup B test strains approximately 4 years after primary vaccination in subjects who previously…
- Trial name
- NCT02451514
- Testing
- MenABCWY+OMV vaccine
- Where
- 7 sites in Chile, Colombia and 1 more
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Invasive Meningococcal Disease
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
This study will evaluate the safety and immunogenicity of combination vaccines as compared to the reference vaccines
- Trial name
- NCT01272180
- Testing
- Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV., Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV., Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
- Where
- 13 sites in United States, Poland
- Volunteers
- 484 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Infection
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
This study is to assess the longevity of immune response in adolescents for approximately 48 months after receipt of a primary series of bivalent rLP2086 vaccination, which is then followed by a booster dose and an assessment of…
- Trial name
- NCT01543087
- Testing
- blood sampling, bivalent rLP2086
- Where
- 56 sites in United States, Czechia and 4 more
- Volunteers
- 698 people, healthy volunteers welcome
- Sponsor
- Pfizer
Meningococcal Disease
PRIME Follow up - Quadri Meningo Vacinees
A previous cohort of 93 clinical trial participants received quadrivalent meningococcal conjugate vaccine, which includes strains ACW and Y, in their teenage years.
- Trial name
- PRIMEfollowup (NCT02811120)
- Testing
- venepuncture only
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Public Health England
Meningitis, Meningococcal
Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years
The purpose of the current study is to evaluate whether there is immune interference when MenABCWY [consisting of MenACWY lyophilized component and rMenB+OMV NZ (Bexsero) liquid component] is administered to healthy adolescents…
- Trial name
- NCT03587207
- Testing
- MenABCWY vaccine, rMenB+OMV NZ (Bexsero) vaccine, MenACWY (Menveo) vaccine
- Where
- Czechia
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Vaccine
MenB Vaccine: Implementation Via Information, Empowerment and Accessibility
As part of an effort to increase MenB vaccine uptake among adolescents and young adults, study teams will conduct qualitative research to maximize the effectiveness of nationally recommended MenB educational materials.
- Trial name
- MenBVaccine (NCT02975596)
- Testing
- Awareness, Education, Empowerment
- Where
- 6 sites in United States
- Volunteers
- 1,326 people, healthy volunteers welcome
- Sponsor
- University of Florida
Meningococcal Infections
Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.
A single-center and open-labeled Phase I study, designed to evaluate the safety by observing the occurrence of adverse events and change of hematology, liver and renal function after vaccination of a meningococcal group A, C, Y…
- Trial name
- NCT04236960
- Testing
- Meningococcal Group ACYW135 Conjugate Vaccine
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.